Physician profile
Robert Smith
NPI 1295754059
$2,866.69
in general payments reported to CMS, 2019-2025
20 companies · $671 in 2025
The $671 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $282 · 2021: $287 · 2022: $301 · 2023: $517 · 2024: $211 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.17 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $609.94 | 2021-2025 | Clareon, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $294.01 | 2019-2022 | |
| Abbvie INC. | $260.97 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Genentech USA, INC. | $252.19 | 2022-2023 | Vabysmo |
| Lensar, INC. | $240.76 | 2020-2025 | Lensar Laser System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $161.29 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $120.75 | 2021 | |
| Ocular Therapeutix, INC. | $117.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.29 | 2020 | |
| Aerie Pharmaceuticals, INC. | $111.04 | 2019 | |
| Astellas Pharma US INC | $110.21 | 2023 | Izervay |
| Rayner Intraocular Lenses Limited | $95.64 | 2024-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Johnson & Johnson Surgical Vision, INC. | $74.87 | 2019 | |
| Bausch & Lomb Americas INC. | $68.66 | 2024-2025 | Scoutpro Osmolarity System, Vyzulta |
| Eyevance Pharmaceuticals LLC | $60.74 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $48.70 | 2025 | Xdemvy |
| Rxsight INC | $41.65 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Lkc Technologies, INC. | $32.25 | 2025 | |
| Shire North American Group INC | $30.90 | 2019 | |
| Oyster Point Pharma, INC. | $22.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.